Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Kaitlin Anstett"'
Autor:
Maureen Oliveira, Ruxandra-Ilinca Ibanescu, Kaitlin Anstett, Thibault Mésplède, Jean-Pierre Routy, Marjorie A. Robbins, Bluma G. Brenner, the Montreal Primary HIV (PHI) Cohort Study Group
Publikováno v:
Retrovirology, Vol 15, Iss 1, Pp 1-14 (2018)
Abstract Background Integrase strand transfer inhibitors (INSTIs) are recommended for first-line HIV therapy based on their relatively high genetic barrier to resistance. Although raltegravir (RAL) and elvitegravir (EVG) resistance profiles are well-
Externí odkaz:
https://doaj.org/article/265839ef403444f0a3ff603f2436c4a3
Publikováno v:
Retrovirology, Vol 14, Iss 1, Pp 1-16 (2017)
Abstract Integrase strand transfer inhibitors (INSTIs) are the newest class of antiretroviral drugs to be approved for treatment and act by inhibiting the essential HIV protein integrase from inserting the viral DNA genome into the host cell’s chro
Externí odkaz:
https://doaj.org/article/0817f80eba7941e8bbb6799e4039ba51
Autor:
Harley O'Connor Mount, Nicole M Revie, Robert T Todd, Kaitlin Anstett, Cathy Collins, Michael Costanzo, Charles Boone, Nicole Robbins, Anna Selmecki, Leah E Cowen
Publikováno v:
PLoS Genetics, Vol 14, Iss 4, p e1007319 (2018)
Invasive fungal infections caused by the pathogen Candida albicans have transitioned from a rare curiosity to a major cause of human mortality. This is in part due to the emergence of resistance to the limited number of antifungals available to treat
Externí odkaz:
https://doaj.org/article/944bb316161947ada1565c081716ea33
Publikováno v:
Journal of Virology. 92
Integrase strand transfer inhibitors (INSTIs) are the newest class of antiretrovirals to be approved for the treatment of HIV infection. Canonical resistance to these competitive inhibitors develops through substitutions in the integrase active site
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48a44fa8ce08aea1b0d47084d01ff443
https://doi.org/10.1128/jvi.01156-18
https://doi.org/10.1128/jvi.01156-18
Autor:
Ruxandra-Ilinca Ibanescu, Kaitlin Anstett, Bluma G. Brenner, Thibault Mesplède, Jean-Pierre Routy, Maureen Oliveira, Marjorie Robbins
Publikováno v:
Retrovirology
Retrovirology, Vol 15, Iss 1, Pp 1-14 (2018)
Retrovirology, Vol 15, Iss 1, Pp 1-14 (2018)
Background Integrase strand transfer inhibitors (INSTIs) are recommended for first-line HIV therapy based on their relatively high genetic barrier to resistance. Although raltegravir (RAL) and elvitegravir (EVG) resistance profiles are well-character
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d7dd3b178ac87607049296744ca9871
https://pubmed.ncbi.nlm.nih.gov/30119633
https://pubmed.ncbi.nlm.nih.gov/30119633
Publikováno v:
Journal of Virology. 89:4681-4684
The new integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) displays limited cross-resistance with older drugs of this class and selects for the R263K substitution in treatment-experienced patients. We performed tissue culture selections w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82319a732a0a5aa07dc85529e25a8dc8
https://doi.org/10.1128/jvi.03485-14
https://doi.org/10.1128/jvi.03485-14
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:310-316
Clinical studies have shown that integrase strand transfer inhibitors (INSTIs) can be used effectively against HIV-1 infection. To date, no resistance substitution has been found in INSTI-naive patients treated with the new integrase inhibitor dolute
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::532a78799c0cb6d6458a00f868410b3c
https://doi.org/10.1128/aac.04274-14
https://doi.org/10.1128/aac.04274-14
Integrase strand transfer inhibitors (INSTIs) are the newest class of antiretrovirals to be approved for the treatment of HIV infection. Canonical resistance to these competitive inhibitors develops through substitutions in the integrase active site
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e891e578b62b4218a96d32bdcc5ff37f
https://europepmc.org/articles/PMC5640858/
https://europepmc.org/articles/PMC5640858/
Publikováno v:
Retrovirology
Retrovirology, Vol 14, Iss 1, Pp 1-16 (2017)
Retrovirology, Vol 14, Iss 1, Pp 1-16 (2017)
Integrase strand transfer inhibitors (INSTIs) are the newest class of antiretroviral drugs to be approved for treatment and act by inhibiting the essential HIV protein integrase from inserting the viral DNA genome into the host cell’s chromatin. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb4e1d3d0e79a8de400fb60d43678733
https://doi.org/10.1186/s12977-017-0360-7
https://doi.org/10.1186/s12977-017-0360-7
Autor:
Nathan Osman, Melissa Wares, Peter K. Quashie, Thibault Mesplède, Diane N. Singhroy, Said Hassounah, Mark A. Wainberg, Ying-Shan Han, Kaitlin Anstett
Publikováno v:
Journal of Antimicrobial Chemotherapy. 69:2733-2740
Background The results of several clinical trials suggest that the integrase inhibitor dolutegravir may be less prone than other drugs to the emergence of HIV drug resistance mutations in treatment-naive patients. We have shown that the R263K mutatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d35b5aac86c575a1b80c90d8f670fc2
https://doi.org/10.1093/jac/dku199
https://doi.org/10.1093/jac/dku199